

Search worldwide, life-sciences literature

CITES:17960406_MED

Search

Advanced Search

[Coronavirus articles and preprints](#) Search examples: "breast cancer" [Smith J](#)

Recent history

Saved searches

Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses.

Fauteck JD¹, Ackermann G, Birkel M, Breuer M, Moor AC, Ebeling A, Ortland C

Author information ►

Archives of Dermatological Research, 25 Oct 2007, 300(2) 53-60

DOI: [10.1007/s00403-007-0787-0](#) PMID: 17960406Share this article [✉](#) [Twitter](#) [LinkedIn](#) [Facebook](#)

Abstract

Actinic keratosis (AK) can be treated by photodynamic therapy (PDT), which is becoming a well-established tool in dermatology. Normally a precursor of the photosensitizer is applied topically and converted into protoporphyrin IX (PPIX) in the cells. By activating PPIX with light, the dysplastic cells will be destroyed. We report the results of two clinical studies investigating the properties of a novel self-adhesive 5-ALA-patch (PD P 506 A) intended for PDT of m to moderate AK on the face and head. The studies investigated the influence of patch application duration on PPIX-specific fluorescence and the pharmacokinetic properties of the 5-ALA patch. The PPIX fluorescence in AK lesions a normal skin after patch application (intraindividual comparison; application for 2, 3, 4, 5 h) was investigated in 13 patients using DYADERM Professional (Biocam). In the subsequent pharmacokinetic study 12 patients were treated with 8 patches each (4 h application). 5-ALA and PPIX were analysed in plasma (over 24 h) and urine (over 12 h). PPIX specific fluorescence measured immediately after patch removal increased with increasing application duration to maximum at 4-h application. The fluorescence in AK lesions was more intense than in normal skin. A small increase of 5-ALA plasma concentrations was observed in 10 of 12 patients after applying 8 patches for 4 h, which rapidly declined to normal values after patch removal. The maximum increase was 3.7-fold of the pre-dose 5-ALA plasma concentration. No PPIX-concentrations above the lower limit of quantification were observed. PPIX-specific fluorescence in AK lesions can be steered by application duration of this novel 5-ALA patch. Application is safe and well tolerable. The observed small rise in 5-ALA plasma concentrations is regarded clinically irrelevant. Clinical efficacy of the patch in PDT will be investigated in further clinical trials.

Full text links

References

Citations & impact

Impact metrics

This website requires cookies, and the limited processing of your personal data. By using the site you are agreeing to this as outlined in our [privacy notice](#).

Biofrontera Exhibit 1034
Biofrontera Inc. et al. v. DUSA Pharmaceuticals, Inc.
IPR2022-00056

Search worldwide, life-sciences literature

CITES:17960406_MED

Search

Advanced Search

[Coronavirus articles and preprints](#) Search examples: "breast cancer" [Smith J](#)

Recent history

Saved searches

Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses.

Fauteck JD¹, Ackermann G, Birkel M, Breuer M, Moor AC, Ebeling A, Ortland C

Author information ►

Archives of Dermatological Research, 25 Oct 2007, 300(2) 53-60

DOI: [10.1007/s00403-007-0787-0](#) PMID: 17960406Share this article [✉](#) [Twitter](#) [LinkedIn](#) [Facebook](#)

Abstract

Actinic keratosis (AK) can be treated by photodynamic therapy (PDT), which is becoming a well-established tool in dermatology. Normally a precursor of the photosensitizer is applied topically and converted into protoporphyrin IX (PPIX) in the cells. By activating PPIX with light, the dysplastic cells will be destroyed. We report the results of two clinical studies investigating the properties of a novel self-adhesive 5-ALA-patch (PD P 506 A) intended for PDT of m to moderate AK on the face and head. The studies investigated the influence of patch application duration on PPIX-specific fluorescence and the pharmacokinetic properties of the 5-ALA patch. The PPIX fluorescence in AK lesions a normal skin after patch application (intraindividual comparison; application for 2, 3, 4, 5 h) was investigated in 13 patients using DYADERM Professional (Biocam). In the subsequent pharmacokinetic study 12 patients were treated with 8 patches each (4 h application). 5-ALA and PPIX were analysed in plasma (over 24 h) and urine (over 12 h). PPIX specific fluorescence measured immediately after patch removal increased with increasing application duration to maximum at 4-h application. The fluorescence in AK lesions was more intense than in normal skin. A small increase of 5-ALA plasma concentrations was observed in 10 of 12 patients after applying 8 patches for 4 h, which rapidly declined to normal values after patch removal. The maximum increase was 3.7-fold of the pre-dose 5-ALA plasma concentration. No PPIX-concentrations above the lower limit of quantification were observed. PPIX-specific fluorescence in AK lesions can be steered by application duration of this novel 5-ALA patch. Application is safe and well tolerable. The observed small rise in 5-ALA plasma concentrations is regarded clinically irrelevant. Clinical efficacy of the patch in PDT will be investigated in further clinical trials.

Full text links

References


Citations & impact

Impact metrics

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our [privacy notice](#) and [cookie policy](#).

I agree, dismiss this banner

Citations of article over time

Smart citations by scite.ai [?](#)

Explore citation contexts and check if this article has been supported or disputed.

<https://scite.ai/reports/10.1007/s00403-007-0787-0> [?](#)

Supporting [✔](#) 1
 Mentioning [🗨](#) 27
 Contrasting [❓](#) 0

Article citations

Smartphone fluorescence imager for quantitative dosimetry of protoporphyrin-IX-based photodynamic therapy in skin.

Ruiz AJ, LaRoche EPM, Gunn JR, Hull SM, Hasan T, Chapman MS, Pogue BW
 J Biomed Opt, 25(6):1-13, 01 Dec 2019
 Cited by: 1 article | PMID: 31820594 | PMCID: PMC6901011

[Free to read & use](#)

Photodynamic therapy simplified: nonprepared, moderate-grade actinic keratosis lesions respond equally well to 5-aminolaevulinic acid patch photodynamic therapy as do mild lesions.

Szeimies RM, Hauschild A, Ortland C, Moor AC, Stocker M, Surber C
 Br J Dermatol, 173(5):1277-1279, 26 Aug 2015
 Cited by: 3 articles | PMID: 25940103

PpIX fluorescence combined with auto-fluorescence is more accurate than PpIX fluorescence alone in fluorescence detection of non melanoma skin cancer an intra patient direct comparison study

van der Beek N, de Leeuw J, Demmendaal C, Bjerring P, Neumann HA
 Lasers Surg Med, 44(4):271-276, 13 Dec 2011
 Cited by: 6 articles | PMID: 22170313

New aspects in photodynamic therapy of actinic keratoses.

Smits T, Moor AC
 J Photochem Photobiol B, 96(3):159-169, 13 Jun 2009
 Cited by: 5 articles | PMID: 19592269

[Review](#)

An overview of topical photodynamic therapy in dermatology.

Ibbotson SH
 Photodiagnosis Photodyn Ther, 7(1):16-23, 29 Dec 2009
 Cited by: 17 articles | PMID: 20230989

[Abstract](#)

[Full text](#) [?](#)

[References](#)

[Citations & impact](#)

[Similar Articles](#)

Similar Articles

About

About Europe PMC
Funders
Joining Europe PMC
Governance
Roadmap
Outreach

Tools

Tools overview
ORCID article claiming
Journal list
Grant finder
External links service
RSS feeds
Annotations
Annotations submission service

Developers

Developer resources
Articles RESTful API
Grants RESTful API
API case studies
SOAP web service
Annotations API
OAI service
Bulk downloads
Developers Forum

Help

Help using Europe PMC
Search syntax reference
Contact us

Let us know how we are doing



Europe PMC is part of the ELIXIR infrastructure

Europe PMC is an ELIXIR Core Data Resource [Learn more >](#)

Europe PMC is a service of the [Europe PMC Funders' Group](#), in partnership with the [European Bioinformatics Institute](#); and in cooperation with the National Center for Biotechnology Information and includes content provided to the PMC International archive by participating publishers.



[Contact us](#) | [Privacy](#) | [Terms of use](#) | [Copyright](#) | [Accessibility](#)

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our [privacy notice](#) and [cookie policy](#).

[I agree, dismiss this banner](#)

Search worldwide, life-sciences literature

CITES:17960406_MED

Search

Advanced Search

[Coronavirus articles and preprints](#) Search examples: ["breast cancer"](#) [Smith J](#)

Recent history

Saved searches

1-9 of 9 results

Sort by: Date received

Search only

Type

- ☐ Research articles (7)
- ☐ Reviews (2)
- ☐ Preprints (0)

Free full text

- ☐ Free to read (1)
- ☐ Free to read & use (1)

Date

- ☐ 2019 (1)
- ☐ 2015 (1)
- ☐ 2011 (1)

Custom date range

Smartphone fluorescence imager for quantitative dosimetry of protoporphyrin-IX-based photodynamic therapy in skin.

Ruiz AJ, LaRochelle EPM, Gunn JR, Hull SM, Hasan T, Chapman MS, Pogue BW

J Biomed Opt, 25(6):1-13, 01 Dec 2019

Cited by: 1 article | PMID: 31820594 | PMCID: PMC6901011

+ Add to export list

Free to read &

Photodynamic therapy simplified: nonprepared, moderate-grade actinic keratosis lesions respond equally to 5-aminolaevulinic acid patch photodynamic therapy as do mild lesions.

Szeimies RM, Hauschild A, Ortland C, Moor AC, Stocker M, Surber C

Br J Dermatol, 173(5):1277-1279, 26 Aug 2015

Cited by: 3 articles | PMID: 25940103

+ Add to export list

PpIX fluorescence combined with auto-fluorescence is more accurate than PpIX fluorescence alone in fluorescence detection of non-melanoma skin cancer: an intra-patient direct comparison study.

van der Beek N, de Leeuw J, Demmendaal C, Bjerring P, Neumann HA

Lasers Surg Med, 44(4):271-276, 13 Dec 2011

Cited by: 6 articles | PMID: 22170313

+ Add to export list

An overview of topical photodynamic therapy in dermatology.

Ibbotson SH

Photodiagnosis Photodyn Ther, 7(1):16-23, 29 Dec 2009

Cited by: 17 articles | PMID: 20230989

+ Add to export list

Rev

Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 month data.

Szeimies RM, Stockfleth E, Popp G, Borrosch F, Brünig H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Hauschild A

Br J Dermatol, 162(2):410-414, 30 Jun 2009

Cited by: 26 articles | PMID: 19804593

+ Add to export list

New aspects in photodynamic therapy of actinic keratoses.

Smits T, Moor AC

J Photochem Photobiol B, 96(3):159-169, 13 Jun 2009

Cited by: 5 articles | PMID: 19592269

+ Add to export list

Rev

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

I agree, dismiss this banner

Lasers Surg Med, 41(2):96-103, 01 Feb 2009

Cited by: 21 articles | PMID: 19226578

[+ Add to export list](#)

Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of a randomized controlled phase III studies.

Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor A, Stocker M, Ortland C, Brunnert M, Szeimies RM

Br J Dermatol, 160(5):1066-1074, 16 Feb 2009

Cited by: 39 articles | PMID: 19222455

[+ Add to export list](#)

Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch.

Hauschild A, Popp G, Stockfleth E, Meyer KG, Imberger D, Mohr P, Itschert G, Kaufmann R, Neuber K, Frambach Gollnick H, Brunnert M, Stocker M, Ortland C, Karrer S

Exp Dermatol, 18(2):116-121, 17 Jul 2008

Cited by: 21 articles | PMID: 18643849

[+ Add to export list](#)

1-9 of 9 results

About

[About Europe PMC](#)
[Funders](#)
[Joining Europe PMC](#)
[Governance](#)
[Roadmap](#)
[Outreach](#)

Tools

[Tools overview](#)
[ORCID article claiming](#)
[Journal list](#)
[Grant finder](#)
[External links service](#)
[RSS feeds](#)
[Annotations](#)
[Annotations submission service](#)

Developers

[Developer resources](#)
[Articles RESTful API](#)
[Grants RESTful API](#)
[API case studies](#)
[SOAP web service](#)
[Annotations API](#)
[OAI service](#)
[Bulk downloads](#)
[Developers Forum](#)

Help

[Help using Europe PMC](#)
[Search syntax reference](#)
[Contact us](#)

C

[Hi](#)
[Fe](#)
[Tv](#)
[Bl](#)
[Te](#)
[Di](#)

Let us know how we are doing.

Europe PMC is part of the ELIXIR infrastructure

Europe PMC is an ELIXIR Core Data Resource [Learn more >](#)

Europe PMC is a service of the Europe PMC Funders' Group, in partnership with the European Bioinformatics Institute ; and in cooperation with the National Center for Biotechnology Information a includes content provided to the PMC International archive by participating publishers.



[Contact us](#) | [Privacy](#) | [Terms of use](#) | [Copyright](#) | [Accessibility](#)

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our [privacy notice](#) and [cookie policy](#).

[I agree, dismiss this banner](#)